JP2005507944A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507944A5
JP2005507944A5 JP2003541742A JP2003541742A JP2005507944A5 JP 2005507944 A5 JP2005507944 A5 JP 2005507944A5 JP 2003541742 A JP2003541742 A JP 2003541742A JP 2003541742 A JP2003541742 A JP 2003541742A JP 2005507944 A5 JP2005507944 A5 JP 2005507944A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
rna
ribonucleoside
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003541742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507944A (ja
Filing date
Publication date
Priority claimed from GB0126701A external-priority patent/GB0126701D0/en
Priority claimed from US10/207,005 external-priority patent/US7049303B2/en
Application filed filed Critical
Publication of JP2005507944A publication Critical patent/JP2005507944A/ja
Publication of JP2005507944A5 publication Critical patent/JP2005507944A5/ja
Withdrawn legal-status Critical Current

Links

JP2003541742A 2001-11-07 2002-11-07 ウイルスの抑制における改善およびその関連 Withdrawn JP2005507944A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0126701A GB0126701D0 (en) 2001-11-07 2001-11-07 Improvements in or relating to induction of mutations in viruses
US10/207,005 US7049303B2 (en) 2001-11-07 2002-07-30 Inhibition of viruses
PCT/GB2002/005031 WO2003039450A2 (en) 2001-11-07 2002-11-07 Improvements in or relating to inhibition of viruses

Publications (2)

Publication Number Publication Date
JP2005507944A JP2005507944A (ja) 2005-03-24
JP2005507944A5 true JP2005507944A5 (enExample) 2006-01-12

Family

ID=26246745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541742A Withdrawn JP2005507944A (ja) 2001-11-07 2002-11-07 ウイルスの抑制における改善およびその関連

Country Status (5)

Country Link
US (2) US7049303B2 (enExample)
EP (1) EP1441744A2 (enExample)
JP (1) JP2005507944A (enExample)
AU (1) AU2002337388A1 (enExample)
WO (1) WO2003039450A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
EP1572097A4 (en) * 2002-09-30 2010-02-17 Smithkline Beecham Corp NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
CA2543116A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
BRPI0510929A (pt) 2004-06-18 2007-07-17 Chiron Corp derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer
CA2600886A1 (en) * 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
ES2540964T3 (es) * 2009-06-08 2015-07-15 Takeda Pharmaceutical Company Limited Compuestos de dihidropirrolonaftiridinona como inhibidores de JAK
HK1214270A1 (zh) * 2012-10-29 2016-07-22 共晶制药股份有限公司 用於治療病毒感染和癌症的嘧啶核苷及其單磷酸酯前藥
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
WO2023152709A1 (en) * 2022-02-14 2023-08-17 Arbutus Biopharma Corporation Rna polymerase inhibitors and methods using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
EP0375183A1 (en) 1988-12-05 1990-06-27 Schering Corporation Antiviral dimers and trimers
DK62592D0 (enExample) * 1992-05-14 1992-05-14 Novo Nordisk As
US5773424A (en) 1994-12-16 1998-06-30 Research Corporation Technologies, Inc. Treatment of toxoplasmosis
PT831852E (pt) 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
BR9714349A (pt) 1996-10-16 2000-11-14 Icn Pharmaceuticals L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
NZ507848A (en) * 1996-10-28 2005-01-28 Univ Washington Method of increasing the mutation rate of a virus in a non-human by administering an RNA nucleoside analogue to a virally infected cell
WO1999043691A1 (en) 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP2003524636A (ja) 1999-12-22 2003-08-19 インスパイアー ファーマシューティカルズ，インコーポレイティド プリン性受容体アゴニストによる胃腸管の処置方法

Similar Documents

Publication Publication Date Title
RU2011139180A (ru) Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции
CA2632626A1 (en) Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
JP2005507944A5 (enExample)
JP2022537047A5 (enExample)
JP2818299B2 (ja) ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用
GB2613516A (en) Formulations of anti-viral compounds
KR20050044587A (ko) Ｂ형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도
WO2010031832A9 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
CA2373833A1 (en) Medicinal compositions for preventing or treating viral myocarditis
JP2022531251A5 (enExample)
JP2018532797A5 (enExample)
JP2025508656A5 (enExample)
JPWO2023054732A5 (enExample)
CZ20011130A3 (cs) Sloučenina, farmaceutický prostředek a jejich použití pro ribavirin-interferon alfa kombinovanou terapii
KR940010441B1 (ko) B형감염의 항비루스제
JP2024544532A5 (enExample)
KR950701638A (ko) 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues)
CN1943782A (zh) 治疗禽流感感染
JP2023502053A5 (enExample)
JP2002533470A5 (enExample)
EP0137807A1 (en) Antiviral composition and method for administering the same
EP3600332B1 (en) Hiv post-exposure prophylaxis
HK1048951A1 (zh) 与PEG-IFN-α结合的霉酚酸酯MOFETIL
WO2000051615B1 (en) Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
Chou Advances in antiviral therapy